CRISPR/Cas9 image

Selumetinib Granted U.S. Breakthrough Therapy Designation in Neurofibromatosis Type 1

Designation Based on Phase 2 SPRINT Trial in Pediatric Patients with NF1 Plexiform Neurofibromas Selumetinib Is a MEK 1/2 Inhibitor Being Co-Developed by AstraZeneca and Merck KENILWORTH, N.J.–(BUSINESS WIRE)– AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted…

Gus Make a Wish Hawaii Trip

Gus and His Make-A-Wish Trip To Hawaii

When 3-year-old Gus Erickson was granted a wish by the Make-A-Wish organization, he told his mom and dad he wished for a piece of candy.  Respecting this wish, his parents relayed it to Gus’ Make-A-Wish Minnesota coordinator.  Her response: “Let’s give him some time to think of something bigger—and better—than…candy.” Gus was born with Neurofibromatosis…